LOISE WAMEITHI: Open Payments
NPI 1134810344 · LENEXA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,388 in 77 payments from 14 companies in 2025. Trend: 2023 $20 · 2024 $313 · 2025 $1,388
Food & beverage: $1,388
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $220 |
| Axsome Therapeutics, Inc. | 15 | $215 |
| Neurocrine BioSciences, Inc. | 3 | $183 |
| Otsuka America Pharmaceutical, Inc. | 11 | $164 |
| Lundbeck LLC | 5 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Supernus Pharmaceuticals, Inc. | 4 | $67 |
| Tris Pharma Inc | 4 | $63 |
| ABBVIE INC. | 3 | $60 |
Products named: REXULTI, HETLIOZ, Auvelity, INGREZZA, CAPLYTA, AUSTEDO XR, Qelbree, Dyanavel XR.
Industry payments across KS — which companies pay providers there.
